Hancock Jaffe Laboratories Inc (HJLI) CEO Acquires $25,001.00 in Stock

Hancock Jaffe Laboratories Inc (NASDAQ:HJLI) CEO Robert Andrew Berman acquired 21,740 shares of the stock in a transaction that occurred on Tuesday, March 12th. The shares were bought at an average cost of $1.15 per share, for a total transaction of $25,001.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

HJLI stock traded up $0.26 during trading hours on Friday, hitting $2.35. The company’s stock had a trading volume of 606,471 shares, compared to its average volume of 147,820. Hancock Jaffe Laboratories Inc has a 12 month low of $1.31 and a 12 month high of $5.64.

HJLI has been the topic of a number of research analyst reports. Zacks Investment Research raised shares of Hancock Jaffe Laboratories from a “hold” rating to a “buy” rating and set a $1.75 price objective on the stock in a research report on Friday, January 4th. ValuEngine downgraded shares of Hancock Jaffe Laboratories from a “buy” rating to a “hold” rating in a research report on Friday, December 21st.

Hedge funds have recently bought and sold shares of the business. Vanguard Group Inc bought a new stake in Hancock Jaffe Laboratories in the third quarter worth approximately $141,000. Vanguard Group Inc. bought a new stake in Hancock Jaffe Laboratories in the third quarter worth approximately $141,000. Finally, Jane Street Group LLC bought a new stake in Hancock Jaffe Laboratories in the fourth quarter worth approximately $47,000. 1.79% of the stock is owned by institutional investors.

WARNING: “Hancock Jaffe Laboratories Inc (HJLI) CEO Acquires $25,001.00 in Stock” was reported by Modern Readers and is the sole property of of Modern Readers. If you are reading this article on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.modernreaders.com/news/2019/03/17/hancock-jaffe-laboratories-inc-hjli-ceo-acquires-25001-00-in-stock.html.

About Hancock Jaffe Laboratories

Hancock Jaffe Laboratories, Inc, a development stage medical device company, develops and sells biological tissue solutions to treat patients with coronary, vascular, end stage renal, and peripheral arterial diseases in the United States and Europe. The company develops and manufactures implantable cardiovascular bioprosthetic devices for patients with cardiovascular disease, peripheral arterial and venous disease, and end stage renal disease.

See Also: Quiet Period Expirations

Receive News & Ratings for Hancock Jaffe Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hancock Jaffe Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.